Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.51 |
| ▸ | BACE1 | P56817 | 2/20 | 0.49 |
| ▸ | REN | P00797 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8281497 | 1.00 | KLK5 (0.51) | KLK5BACE1RENATMCTSL | |
| SCHEMBL13390560 | 1.00 | KLK5 (0.51) | KLK5BACE1RENATMCTSL | |
| SCHEMBL7274993 | 0.94 | KLK5 (0.55) | KLK5BACE1RENATMCTSL | |
| SCHEMBL3049388 | 0.85 | BACE1 (0.52) | BACE1 | |
| SCHEMBL3046920 | 0.85 | BACE1 (0.52) | BACE1 | |
| SCHEMBL3042249 | 0.85 | BACE1 (0.52) | BACE1 | |
| SCHEMBL3042030 | 0.85 | BACE1 (0.52) | BACE1 | |
| SCHEMBL6444857 | 0.83 | KLK5 (0.63) | KLK5ATMCTSLACECTSS | |
| SCHEMBL6446193 | 0.83 | KLK5 (0.63) | KLK5ATMCTSLACECTSS | |
| SCHEMBL6445261 | 0.83 | KLK5 (0.63) | KLK5ATMCTSLACECTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691818-B2 | Peptidomimetic inhibitors of retroviral proteases and their use as antivirals | Universita' Degli Studi Di Treiste (IT) | 2010-04-06 | — | — | US | disclosed |
| US-7691818-B2 | Peptidomimetic inhibitors of retroviral proteases and their use as antivirals | Universita' Degli Studi Di Treiste (IT) | 2010-04-06 | — | — | US | disclosed |
| EP-1768665-B1 | PEPTIDOMIMETIC INHIBITORS OF HIV PROTEASE | UNIV DEGLI STUDI TRIESTE (IT) | 2008-11-05 | — | — | EP | disclosed |
| US-20070207968-A1 | Peptidomimetic Inhibitors Of Retroviral Proteases And Their Use As Antivirals | UNIVERSITA' DEGLI STUDI DI TRIESTE (IT) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207968-A1 | Peptidomimetic Inhibitors Of Retroviral Proteases And Their Use As Antivirals | PREP, PEPD, DNPEP | KLK5 3017/4885BACE1 73/4885REN 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.